×
About 5,745 results

ALLMedicine™ Lupus Nephritis Center

Research & Reviews  2,020 results

Immune System Related Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT00001979

May 20th, 2022 - This study evaluates participants with known or suspected immunologically-mediated kidney diseases, including but not limited to nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with other s...

Identification of ferroptosis-related molecular markers in glomeruli and tubulointersti...
https://doi.org/10.1177/09612033221102076
Lupus Wang W, Lin Z et. al.

May 20th, 2022 - Ferroptosis, characterized by iron accumulation and lipid peroxidation, is a newly demonstrated form of programed cell death. Present studies reveal that ferroptosis is involved in tumor and neurodegenerative disease. Regarding its roles in the de...

Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.
https://doi.org/10.1080/21645515.2022.2072143
Human Vaccines & Immunotherapeutics; Plüß M, Piantoni S et. al.

May 20th, 2022 - In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complica...

Glomerular Exostosin as a Subtype and Activity Marker of Class V Lupus Nephritis.
https://doi.org/10.2215/CJN.00350122
Clinical Journal of the American Society of Nephrology : ... Wang C, Liu Y et. al.

May 19th, 2022 - Background and objectives There have been only several studies on the correlation between glomerular exostosin expression and membranous lupus nephritis. In this study, we validate the previous findings in Chinese patients with class V lupus nephr...

see more →

Guidelines  5 results

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
https://doi.org/10.1016/j.kint.2021.05.015
Kidney International; Rovin BH, Adler SG et. al.

Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...

2019 Update of the Joint European League Against Rheumatism and European Renal Associat...
https://doi.org/10.1136/annrheumdis-2020-216924
Annals of the Rheumatic Diseases; Fanouriakis A, Kostopoulou M et. al.

Mar 30th, 2020 - To update the 2012 EULAR/ERA-EDTA recommendations for the management of lupus nephritis (LN). Following the EULAR standardised operating procedures, a systematic literature review was performed. Members of a multidisciplinary Task Force voted inde...

Revision of the International Society of Nephrology/Renal Pathology Society classificat...
https://doi.org/10.1016/j.kint.2017.11.023
Kidney International; Bajema IM, Wilhelmus S et. al.

Feb 21st, 2018 - We present a consensus report pertaining to the improved clarity of definitions and classification of glomerular lesions in lupus nephritis that derived from a meeting of 18 members of an international nephropathology working group in Leiden, Neth...

Overview of lupus nephritis management guidelines and perspective from Asia.
https://doi.org/10.1111/1756-185X.12212
International Journal of Rheumatic Diseases; Mok CC, Yap DY et. al.

Jan 3rd, 2014 - Lupus nephritis (LN) is a common and important manifestation of systemic lupus erythematosus (SLE). Evidence suggests higher rates of lupus renal involvement in Asian populations, and maybe more severe nephritis, compared with other racial or ethn...

American College of Rheumatology guidelines for screening, treatment, and management of...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437757
Arthritis Care & Research; Hahn BH, McMahon MA et. al.

May 5th, 2012 - American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.|2012|Hahn BH,McMahon MA,Wilkinson A,Wallace WD,Daikh DI,|diagnosis,therapy,methods,

see more →

Drugs  3 results see all →

Clinicaltrials.gov  63 results

Immune System Related Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT00001979

May 20th, 2022 - This study evaluates participants with known or suspected immunologically-mediated kidney diseases, including but not limited to nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with other s...

Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
https://clinicaltrials.gov/ct2/show/NCT04643470

Apr 21st, 2022 - The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)
https://clinicaltrials.gov/ct2/show/NCT05097989

Apr 20th, 2022 - This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤ 75 years of age) w...

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
https://clinicaltrials.gov/ct2/show/NCT04564339

Mar 16th, 2022 - This study consists of a 6-week Screening Period, 26-week Initial Evaluation Period, a 24-week Extension Period, and a 36-week post-treatment Follow-up Period.

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
https://clinicaltrials.gov/ct2/show/NCT01085097

Mar 9th, 2022 - The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules in active lupus nephritis participants. This study will assess Laquinimod doses of 0.5 milligrams (mg)/day and 1 mg/day in combination with ...

see more →

News  204 results

Expanded Treatment Options for Lupus Nephritis
https://www.mdedge.com/rheumatology/article/254271/lupus-connective-tissue-diseases/expanded-treatment-options-lupus
Joan Merrill, MD

May 6th, 2022 - Lupus nephritis (LN) affects approximately 25%-60% of patients with systemic lupus erythematosus. Currently, guideline-directed therapy recommends a combination of steroids plus either mycophenolate mofetil or cyclophosphamide.

Mixed Results for Oral Lupus Drug in Phase II
https://www.medpagetoday.com/rheumatology/lupus/97690

Mar 16th, 2022 - What could be the first oral medication specific for systemic lupus erythematosus (SLE) was more effective than placebo in a randomized phase II trial, though the results were something less than a home run. With 288 patients assigned to three dos...

Health Disparities Exist Across Rheumatology: What Can Be Done?
https://www.medscape.com/viewarticle/969350

Feb 28th, 2022 - Disparities in healthcare exist in every specialty. In rheumatology, health disparities look like lack of access to care and lack of education on the part of rheumatologists and their patients, according to a speaker at the 2022 Rheumatology Winte...

Rheumatologists More Likely Than Nephrologists to Use Rituximab in Kids With Lupus Nephritis
https://www.medscape.com/viewarticle/958701

Sep 15th, 2021 - NEW YORK (Reuters Health) - Pediatric rheumatologists and nephrologists appear to differ in their treatment choices for children who have lupus nephritis (LN), with rheumatologists more likely to prescribe rituximab, results of a small survey sugg...

FDA Drug Approvals, Nephrology and Urology — 2021 Midyear Review
https://www.medscape.com/viewarticle/956207

Aug 20th, 2021 - Lupkynis (voclosporin) Voclosporin is an oral calcineurin inhibitor indicated in combination with a background immunosuppressive regimen for treatment of active lupus nephritis in adults. The AURA-LV phase 3 trial randomized patients to placebo or...

see more →

Patient Education  3 results see all →